Tissue Regenix Group PLC (AIM:TRX, OTC:TSSNF) chief executive Danny Lee and chief financial officer David Cocke speak to Proactive's Thomas Warner after releasing a trading update for 2022.
They reveal their highlights from the year before looking ahead to what investors can expect from the business during 2023.
Lee says that Tissue Regenix "has the opportunity to become a global commercial organisation."